EDMONTON, ALBERTA -- (MARKET WIRE) -- May 30, 2007 -- ViRexx Medical Corp. (TSX: VIR) (AMEX: REX), a company focused on immunotherapy treatments for certain cancers, chronic hepatitis B & C and embolotherapy treatments for tumors, today announced that it has signed collaboration agreements with the National Research Council Canada’s National Institute for Nanotechnology (NINT) and Defence Research and Development Canada Suffield (DRDC Suffield) with networking and financial contribution from NRC-IRAP.
